Fibromuscular Dysplasia - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The fibromuscular dysplasia market is projected to expand from USD 0.85 billion in 2025 and USD 0.90 billion in 2026 to USD 1.23 billion by 2031, registering a CAGR of 6.33% between 2026 and 2031. This report is segmented by Disease Type (Renal Fibromuscular Dysplasia, Cervical Fibromuscular Dysplasia, and More), Component (Treatment Type, Diagnosis Method), Age Group (Pediatric, Adult, Geriatric), End-User (Hospitals, Specialty Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Fibromuscular Dysplasia Market Trends and Insights

Greater Recognition of FMD as a Systemic Arteriopathy

Fibromuscular dysplasia is increasingly managed as a systemic arterial disorder rather than a condition restricted to the renal or cervical arteries. The ARCADIA Registry review reported multisystem vascular involvement in 66% of patients, including lesions in a second arterial bed for 48% and aneurysms or dissections for 18%. These findings support broader assessment after diagnosis and increase the number of clinical services used per patient. In 2026, RadioGraphics described the expanding role of radiologists in identifying multisystem manifestations and related complications. The fibromuscular dysplasia market therefore benefits when nephrology, neurology, radiology, and vascular teams recognize the same patient pathway. Registry evidence also supports earlier diagnosis and more consistent follow-up across specialized centers.

Wider Adoption of CTA and MRA for Multivessel Screening

CTA and MRA are becoming central to initial multivessel assessment in the fibromuscular dysplasia market. The 2025 ESVS guidance supports cross-sectional imaging to confirm renal FMD and define clinically relevant arterial disease. CTA offers high spatial resolution, identifies calcification, and is widely available, while MRA is useful when radiation exposure or iodinated contrast is a concern. Head-to-pelvis protocols can move assessment from separate examinations to a structured single diagnostic pathway. That change raises scanner use per confirmed case and favors providers with established CTA and MRA capacity. Ultrasound remains useful for initial renal assessment and surveillance, but it is less likely to be the only confirmatory examination.

Prolonged Diagnostic Delay and Underdiagnosis

Diagnostic delay remains a major limitation because symptoms can overlap with essential hypertension, migraine, and vasculitis. Registry evidence in the supplied research placed the period from first symptom to diagnosis between 3.6 and 9 years. The commercial pathway begins only after a diagnosis is confirmed, so delays restrict the treated population in the fibromuscular dysplasia market. Available prevalence estimates from autopsy and donor angiography studies have exceeded registry-based diagnosed populations, indicating a sizeable pool that remains unrecognized. This gap makes production planning more difficult for device suppliers and limits the predictability of demand. The issue is most pronounced where referral systems and vascular imaging access remain limited.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Specialized FMD Clinics and Multidisciplinary Care
• Increasing Use of Image-Guided Endovascular Intervention
• Limited Randomized Evidence for FMD-Specific Therapies

Segment Analysis

Renal FMD held 39.61% of the segment in 2025, making it the largest disease subtype in the fibromuscular dysplasia market. Its position reflects the established clinical pathway for renal artery disease and the high prevalence of renal involvement described in clinical references. A study of Chinese patients with renal artery FMD also supported the safety and effectiveness of endovascular management for blood pressure reduction. Renal disease remains the main clinical entry point for many patients.

Vertebral FMD is projected to grow at a 7.14% CAGR through 2031, the fastest rate among disease subtypes. Greater neurological recognition links vertebral involvement to posterior circulation stroke and cervical artery dissection. Cervical disease can therefore lead to neurovascular assessment as well as ongoing imaging surveillance. Visceral and iliac FMD remain smaller categories, although systematic cross-sectional imaging identifies lesions that were previously incidental. The broader detection of these arterial sites expands the clinical scope of the fibromuscular dysplasia industry.

Treatment type accounted for 51.37% of the fibromuscular dysplasia market in 2025, making it the largest component segment. The treatment landscape includes antihypertensive medications, antiplatelet therapy, endovascular interventions, and surgical procedures aimed at controlling symptoms, managing blood pressure, and reducing the risk of vascular complications. Treatment remains the primary revenue-generating component due to the chronic nature of disease management and the need for ongoing clinical intervention.

Diagnosis method is projected to grow at a CAGR of 8.27% through 2031, the fastest among the component segments. Growth is driven by increasing awareness of FMD, improved access to advanced imaging technologies, and greater utilization of diagnostic modalities such as computed tomography angiography (CTA), magnetic resonance angiography (MRA), duplex ultrasound, and catheter-based angiography. Earlier detection and expanded screening of at-risk patients are expected to support continued growth in diagnostic testing.

Complete Report Scope:

• By Disease Type
  • Renal Fibromuscular Dysplasia
  • Cervical Fibromuscular Dysplasia
  • Carotid Fibromuscular Dysplasia
  • Vertebral Fibromuscular Dysplasia
  • Other Etiologies
• By Component
  • Treatment Type
    • Medications
    • Surgical Interventions
    • Radiological Interventions
    • Endovascular Interventions
  • Diagnosis Method
    • Ultrasound
    • Magnetic Resonance Angiography
    • Computed Tomography Angiography
    • Conventional Angiography
• By Age Group
  • Pediatric
  • Adult
  • Geriatric
• By End-User
  • Hospitals
  • Specialty Clinics
  • Diagnostic Imaging Centers
  • Other End-Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 47.16% of the fibromuscular dysplasia market in 2025. The region combines established registries, specialized centers, and reimbursement pathways that support higher use per diagnosed patient. The North American FMD Registry has involved specialized centers across the United States and provides a coordinated base for research and follow-up. Cleveland Clinic, UH Harrington Heart and Vascular Institute, and Massachusetts General Hospital are major examples of hospital-centered care. Canada and Mexico add smaller but growing case volumes through referral links and rising awareness from U.S. academic programs.

Europe is the second-largest regional setting in the source material, with the United Kingdom, France, Germany, and Belgium supporting the most developed institutional activity. The national clinic at Salford Royal used a brain-to-pelvis imaging protocol and reported both confirmed FMD and conditions that mimicked FMD. France’s Haute Autorité de Santé recommends angioplasty as the first-line treatment for functional renal artery stenosis due to FMD and requires multidisciplinary review before revascularization decisions. Spain, Italy, and other European countries participate at lower volumes because they have fewer dedicated programs. Fragmented delivery systems and limited specialist access continue to restrain broader use.

Asia-Pacific is projected to grow at an 8.24% CAGR through 2031, the fastest regional rate in the fibromuscular dysplasia market. Rising hypertension detection, expanding healthcare infrastructure, and increased recognition of secondary causes of resistant hypertension support this outlook. Japan leads regional clinical capability through advanced cardiovascular screening and its regulatory framework for innovative medical devices. India and South Korea offer incremental potential as CTA becomes available beyond tertiary hospitals. The Middle East and Africa and South America remain smaller due to constrained imaging access and referral infrastructure, although GCC countries and Brazil are the more developed submarkets.

List of Companies Covered in this Report:

• Abbott Laboratories
• AngioDynamics
• B. Braun
• BIOTRONIK
• Boston Scientific
• Cardinal Health
• Cook Group
• Cordis
• GE HealthCare Technologies Inc.
• Johnson & Johnson MedTech
• Koninklijke Philips
• Medtronic
• Merit Medical Systems
• MicroPort
• Penumbra
• Siemens Healthineers
• Stryker
• Teleflex
• Terumo
• W. L. Gore & Associates

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support